Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.23) earnings per share (EPS) for the quarter, FiscalAI reports.
Hillstream Biopharma Trading Down 2.5%
Shares of NASDAQ CNTN traded down $0.10 during midday trading on Friday, reaching $3.66. 288,641 shares of the company traded hands, compared to its average volume of 775,652. The firm has a market capitalization of $207.09 million, a P/E ratio of -0.92 and a beta of 1.44. The stock’s 50-day moving average is $3.43. Hillstream Biopharma has a 52 week low of $1.08 and a 52 week high of $9.08.
Analyst Ratings Changes
A number of research firms have issued reports on CNTN. Weiss Ratings initiated coverage on shares of Hillstream Biopharma in a research note on Monday, March 9th. They set a “sell (e+)” rating for the company. Wall Street Zen cut Hillstream Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, April 4th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.
Hillstream Biopharma Company Profile
Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.
Featured Stories
- Five stocks we like better than Hillstream Biopharma
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Hillstream Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
